Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2026

Original Article

Epilepsy risk comparison of SGLT2 versus incretin-related therapies

Comparative risk of epilepsy with SGLT2 inhibitors versus incretin-based therapies in type 2 diabetes.

Epilepsia

Citation & Authors

Epilepsia. 2026;.

Fu-Shun Yen; Yu-Hsin Yen; Yao-Min Hung; James Cheng-Chung Wei; Chen-Yu Sung; Yu-Han Huang; Fuu-Jen Tsai; Chii-Min Hwu; Chih-Cheng Hsu

ABSTRACT · RESEARCH SUMMARY

Research summary

This matched Taiwanese National Health Insurance study found that SGLT2 inhibitors were associated with lower risks of seizures, epilepsy, and their composite than DPP-4 inhibitors. Compared with GLP-1 drugs, only the composite was significantly lower (aHR 0.66; p=0.016); individual outcomes were not significantly different. No significant differences were found between GLP-1 drugs and DPP-4 inhibitors.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗